Conformational Analysis of Biotherapeutics by HDX/MS

• Broadcast Date: Wednesday, December 7, 2011
• Time: 10:00 AM EST, 7:00 AM PST

REGISTRATION IS FREE

AVAILABLE ON DEMAND

Hydrogen/deuterium exchange (HDX) combined with mass spectrometry (MS) provides a powerful combination of technologies for the analysis of biotherapeutic protein conformation and examination of higher-order structural dynamics and epitope mapping.

Advances in HDX/MS hardware and software offer biopharmaceutical scientists the ability to monitor the changes in higher-order structure of a therapeutic protein, and examine the protein dynamics and association with other proteins and biomolecules. The powerful combination of Ultra Performance Liquid Chromatography (UPLC), dedicated HDX fluidic automation, high-resolution time-of-flight (Tof) and ion-mobility Tof (IMS-Tof) mass spectrometry, along with purpose-driven software, delivers high spatial resolution and analytical reproducibility with minimal sample consumption.

In this seminar, the first—and only—commercially available system for HDX studies will be discussed by scientists in academia and industry who are actively using the technology in their research. They will illustrate how this automated system removes previous barriers and enables them to readily achieve routine and robust high-performance analytics. Our panelists will also describe how the system’s dedicated HDX processing software simplifies studies of higher-order biotherapeutic protein structure for a variety of applications.

Panelists in this webinar will describe the underlying principles and benefits of HDX/MS analysis, and will demonstrate specific applications of the technology for rapid and meaningful comparability studies.

In This Webinar You Will Learn

• How HDX/MS can be deployed throughout protein biopharmaceutical development organizations.
• How HDX/MS identifies conformation changes of biotherapeutics, including the changes that accompany protein PEGylation.
• How peptide level HDX/MS can reveal local structural changes in response to stability, formulation, and upstream and downstream process production factors.
• How dedicated software tools can quickly enable high-confidence peptide identifications and determinations of deuterium uptake for meaningful assessment of protein structure in convenient display formats.

Who Should Attend

• Biopharmaceutical development scientists
• QA/QC scientists
• Protein biochemists
• Biopharmaceutical manufacturing scientists
• Protein mass spectroscopists
• Protein purification scientists

Panelists Include

• St John Skilton, Ph.D., Senior Manager, Late Stage, Development Pharmaceutical & Life Sciences Business, Operations, Waters
• Morten Beck Trelle, Ph.D., Postdoc, Department of Biochemistry and Molecular Biology, University of Southern Denmark
• Steven Berkowitz, Ph.D., Principal Investigator, Analytical Development, Biogen Idec
• Hui Wei, Ph.D., Research Investigator, Bristol-Myers Squibb

Tamlyn Oliver, Managing Editor, Genetic Engineering & Biotechnology News, will be the host of this webinar. A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

AVAILABLE ON DEMAND